Show simple item record

dc.contributor.authorYengo, Loicen_US
dc.contributor.authorArredouani, Abdelilahen_US
dc.contributor.authorMarre, Michelen_US
dc.contributor.authorRoussel, Ronanen_US
dc.contributor.authorVaxillaire, Martineen_US
dc.contributor.authorFalchi, Marioen_US
dc.contributor.authorHaoudi, Abdelalien_US
dc.contributor.authorTichet, Jeanen_US
dc.contributor.authorBalkau, Beverleyen_US
dc.contributor.authorBonnefond, Amélieen_US
dc.contributor.authorFroguel, Philippeen_US
dc.date.accessioned2016-11-18T20:06:06Z
dc.date.issued2016en_US
dc.identifier.citationYengo, L., A. Arredouani, M. Marre, R. Roussel, M. Vaxillaire, M. Falchi, A. Haoudi, et al. 2016. “Impact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profiling.” Molecular Metabolism 5 (10): 918-925. doi:10.1016/j.molmet.2016.08.011. http://dx.doi.org/10.1016/j.molmet.2016.08.011.en
dc.identifier.issn2212-8778en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:29407756
dc.description.abstractObjective: Characterizing specific metabolites in sub-clinical phases preceding the onset of type 2 diabetes to enable efficient preventive and personalized interventions. Research design and methods We developed predictive models of type 2 diabetes using two strategies. One strategy focused on the probability of incidence only and was based on logistic regression (MRS1); the other strategy accounted for the age at diagnosis of diabetes and was based on Cox regression (MRS2). We assessed 293 metabolites using non-targeted metabolomics in fasting plasma samples of 1,044 participants (including 231 incident cases over 9 years) used as training population; and fasting serum samples of 128 participants (64 incident cases versus 64 controls) used as validation population. We applied a LASSO-based variable selection aiming at maximizing the out-of-sample area under the receiver operating characteristic curve (AROC) and integrated AROC. Results: Sixteen and 17 metabolites were selected for MRS1 and MRS2, respectively, with AROC = 90% and 73% in the training and validation populations, respectively for MRS1. MRS2 had a similar performance and was significantly associated with a younger age of onset of type 2 diabetes (β = −3.44 years per MRS2 SD in the training population, p = 1.56 × 10−7; β = −4.73 years per MRS2 SD in the validation population, p = 4.04 × 10−3). Conclusions: Overall, this study illustrates that metabolomics improves prediction of type 2 diabetes incidence of 4.5% on top of known clinical and biological markers, reaching 90% in total AROC, which is considered the threshold for clinical validity, suggesting it may be used in targeting interventions to prevent type 2 diabetes.en
dc.language.isoen_USen
dc.publisherElsevieren
dc.relation.isversionofdoi:10.1016/j.molmet.2016.08.011en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034686/pdf/en
dash.licenseLAAen_US
dc.subjectType 2 diabetesen
dc.subjectMetabolomicsen
dc.subjectRisk predictionen
dc.subjectHigh dimensional regressionen
dc.subjectLASSOen
dc.titleImpact of statistical models on the prediction of type 2 diabetes using non-targeted metabolomics profilingen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalMolecular Metabolismen
dc.date.available2016-11-18T20:06:06Z
dc.identifier.doi10.1016/j.molmet.2016.08.011*
dash.authorsorderedfalse


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record